```html

Vulvar Herpes – A Comprehensive Medical Guide

Overview

Herpes simplex virus (HSV) infection of the vulva, commonly called vulvar herpes, is a recurring genital infection caused by Herpes simplex virus type 1 (HSV‑1) or type 2 (HSV‑2). The virus infects the skin and mucous membranes of the external genitalia, leading to painful blisters or ulcers.

Both women and people assigned female at birth (AFAB) can develop vulvar herpes. In the United States, approximately 1 in 6 adults (≈15 %) are infected with HSV‑2, and an additional 50 % carry HSV‑1, which increasingly causes genital disease through oral‑genital contact.<sup>1</sup> While many infections are asymptomatic, about 30 % of women will experience recognizable genital lesions at some point in their lives.<sup>2</sup>

Symptoms

The clinical picture of vulvar herpes is variable. Symptoms usually appear within 2–12 days after exposure, but they can recur months or years later.

• Prodrome (early warning signs) – Tingling, itching, burning, or a “pins‑and‑needles” sensation on the vulva or inner thighs. This may last from a few hours to a day before lesions appear.
• Blisters – Small (2–5 mm), fluid‑filled vesicles that can cluster together. They are often translucent or pink and may be painful.
• Ulcers – Vesicles rupture, forming shallow, tender ulcers that may crust over after 5–10 days.
• Pain – Discomfort during walking, sitting, or sexual activity is common.
• Swelling – The vulvar tissue may become edematous, especially during a primary outbreak.
• Systemic symptoms – Fever, headache, muscle aches, and swollen lymph nodes (especially in the groin) may accompany the first episode.
• Recurrent outbreaks – Typically less severe, shorter (3–7 days), and may lack systemic signs.
• Asymptomatic shedding – Up to 70 % of genital HSV infections are clinically silent but can still be transmitted.

Causes and Risk Factors

Vulvar herpes is caused by direct skin‑to‑skin contact with infected secretions.

• HSV‑1 – Historically associated with oral cold sores; now responsible for ~50 % of first‑time genital infections due to oral‑genital sex.
• HSV‑2 – The classic cause of genital herpes; more likely to cause recurrent genital lesions.

Key risk factors include:

• Unprotected vaginal, oral, or anal sex with an infected partner.
• Multiple sexual partners or a new partner whose HSV status is unknown.
• Having another sexually transmitted infection (STI); co‑infection compromises mucosal barriers.
• Poor immune function (e.g., HIV, immunosuppressive medications, chemotherapy).
• Pregnancy – Hormonal changes can increase outbreak frequency.
• Stress, fatigue, or illness – Triggers for recurrent episodes.

Diagnosis

Accurate diagnosis relies on a combination of clinical assessment and laboratory testing.

Clinical Examination

• Visual inspection of characteristic vesicles or ulcers.
• Assessment of prodromal symptoms and patient history (previous outbreaks, partner’s HSV status).

Laboratory Tests

• Polymerase chain reaction (PCR) – The most sensitive test; can differentiate HSV‑1 from HSV‑2 using a swab from an active lesion.
• Viral culture – Useful for lesions that are >24 hours old; less sensitive than PCR.
• Type‑specific serology – Blood tests detecting HSV‑1 and HSV‑2 IgG antibodies. Helpful when lesions are absent but exposure is suspected.
• Tzanck smear – Rapid microscopic exam showing multinucleated giant cells; rarely used today due to low specificity.

When to Test

Testing is recommended for:

• First‑time lesions or atypical presentations.
• Pregnant individuals (to guide delivery decisions).
• Patients with immunocompromise.
• Those seeking counseling about transmission risk.

Treatment Options

There is no cure for HSV, but antiviral therapy can shorten outbreaks, reduce pain, and lower transmission risk.

Antiviral Medications

Drug	Typical Dose (Adults)	Use
Acyclovir	400 mg PO three times daily for 7–10 days (primary) or 400 mg PO twice daily for suppression	First‑line; inexpensive
Valacyclovir	1 g PO twice daily for 7–10 days (primary) or 500 mg PO once daily for suppression	Better bioavailability; convenient dosing
Famciclovir	250 mg PO three times daily for 7–10 days (primary) or 250 mg PO twice daily for suppression	Alternative when intolerance to other agents

For severe primary infections or immunocompromised patients, intravenous acyclovir (5 mg/kg every 8 h) may be required.

Symptom‑Relief Measures

• Pain control – Over‑the‑counter NSAIDs (ibuprofen 200–400 mg q6‑8 h) or acetaminophen.
• Topical anesthetics – Lidocaine 5 % gel or ointment applied 3–4 times daily.
• Cool compresses – Reduce swelling and discomfort.

Lifestyle & Supportive Care

• Keep the area clean and dry; gentle washing with mild, fragrance‑free soap.
• Avoid tight clothing; wear breathable cotton underwear.
• Refrain from sexual activity until lesions have fully crusted (usually 5–7 days).

Living with Vulvar Herpes

Managing a chronic HSV infection is as much about daily habits as medication.

Daily Management Tips

• Know your triggers – Stress, menstrual periods, and illness often precede recurrences. Keep a brief diary to identify patterns.
• Maintain a healthy immune system – Balanced diet, regular exercise, adequate sleep (7–9 h), and stress‑reduction techniques (mindfulness, yoga).
• Safe sex practices – Use condoms or dental dams consistently; discuss HSV status openly with partners.
• Medication adherence – If on suppressive therapy, take the drug at the same time daily to keep viral levels low.
• Pelvic health – Consider pelvic floor physical therapy if chronic pain persists after lesions heal.
• Emotional support – Joining a support group or talking with a therapist can help cope with stigma.

Impact on Pregnancy

Women with genital HSV should inform their obstetrician. Antiviral suppression (valacyclovir 500 mg daily) starting at 36 weeks reduces the risk of delivering a baby with neonatal herpes (<1 % vs. 4–5 % without suppression). A cesarean section is recommended if active lesions are present at the time of labor.<sup>3</sup>

Prevention

While avoiding all risk is impossible, the following strategies markedly lower transmission probability.

• Consistent condom use – Reduces HSV transmission by ~30 %; combine with dental dams for oral contact.
• Suppressive antiviral therapy – Lowers asymptomatic viral shedding by ~70 % (valacyclovir 500 mg daily).<sup>4</sup>
• Partner testing and disclosure – Knowing a partner’s HSV status guides safer‑sex decisions.
• Avoid sexual activity during outbreaks – Viral load peaks when lesions are present.
• Limit alcohol and tobacco – Both can impair immune response.

Complications

Most vulvar herpes infections resolve without lasting problems, but untreated or severe disease can lead to:

• Secondary bacterial infection – Bacterial overgrowth of ulcerated skin, requiring antibiotics.
• Herpes‑associated dermatoses – Erythema multiforme or Stevens‑Johnson syndrome (rare, drug‑related).
• Chronic pain syndromes – Persistent vulvar pain (vulvodynia) after recurrent lesions.
• Neonatal herpes – Rare but life‑threatening if a mother transmits HSV during delivery.
• Increased HIV susceptibility – HSV lesions disrupt mucosal barriers, raising HIV acquisition risk by up to threefold.<sup>5</sup>

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Genital Herpes – CDC Fact Sheet. 2022. https://www.cdc.gov/std/herpes/stdfact-herpes.htm
2. World Health Organization. Herpes simplex virus. 2023. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus
3. Mayo Clinic. Genital herpes and pregnancy. 2024. https://www.mayoclinic.org/diseases-conditions/genital-herpes/in-depth/genital-herpes-pregnancy/art-20486973
4. American Sexual Health Association. Suppressive therapy for genital herpes. 2023. https://www.ashasexualhealth.org/herpes
5. CDC. HSV infection and HIV acquisition. 2022. https://www.cdc.gov/hiv/basics/hsv.html

```